Incyte (INCY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY)

INCY 106.13

-0.1%

1:23 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: James Hutton who wrote (560)	1/14/1998 1:27:00 AM
From: Larry Liebman	Read Replies (1) of 3202

Impressive performance. Company is aggressively pumping profits into R&D at a rate of $3+/share or $80 million/per annum. For the fiscal year ending 12/31/95 R&D was $18 million. For the last quarter( 12/31/97) it was $20 million! If they chose to "cook their books" to impress "The Street" with eps they could certainly do so. With Novartis signing on today, annualized revenues surpassing $100 million, the diagnostic venture, etc., INCY appears extremely well positioned as a core biotech holding. One wonders what will happen when a database partner announces bringing a drug candidate into the clinic or patents are awarded to INCY.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next